ArticleScientific reports2025
Functional discrimination of CSF from Alzheimer's patients in a brain on chip platform.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Blood-brain barrier permeability of adipokines and myokines.Nature reviews. Endocrinology · 2026Article
- Organ-on-a-Chip and Lab-on-a-Chip Technologies in Cardiac Tissue Engineering.Biomimetics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases, including Alzheimer's disease (AD), present significant diagnostic challenges due to overlapping symptoms and the invasive, time-consuming, and costly nature of current diagnostic methods. While AD remains the only neurodegenerative disorder for which biomarkers in cerebrospinal fluid (CSF), such as amyloid beta peptide (Aβ), are available for clinical diagnosis, similar tools are lacking for other neurodegenerative conditions. This diagnostic gap hinders timely and accurate differential diagnoses, limiting patient access to appropriate clinical trials and therapeutic interventions. In this study, we developed a compartmentalized microfluidic platform to facilitate differential diagnosis of neurodegenerative diseases by providing an initial screening tool to guide patients toward targeted clinical pathways. Using CSF samples from AD patients with confirmed diagnoses, we showed a proof of concept to distinguish between non neurodegenerative (NN) and Alzheimer's samples. Human glutamatergic neurons derived from induced pluripotent stem cells (iPSCs) were exposed to synthetic Aβ oligomers (AβO) and patient CSF to assess their effects on neuronal network activity. Neuronal responses were recorded via microelectrode array (MEA) before and after treatments, with tetrodotoxin (TTX) serving as a control for validating modulation of the neuronal network. Our findings demonstrated that key electrophysiological metrics extracted from MEA recordings can tend to differentiate AD from non-neurodegenerative CSF samples. This standardized platform not only provides a robust approach for AD biomarker validation but also offers a foundation for broader differential diagnosis of neurodegenerative diseases. By enabling more accurate patient stratification, this tool could have the potential to direct patients toward appropriate clinical trials, enabling the diagnosis of a broader range of neurodegenerative diseases. This approach has the potential to expand the patient population included in research and accelerate the development of new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.